4 months after drug approval, Achaogen eyes fire sale

Antibiotic drug maker Achaogen Inc., which in June won regulatory approval for its first antibiotic drug, said Monday it is exploring "strategic alternatives," including a possible sale or merger, as the once-fast-growing company lays off more employees. The South San Francisco company's troubles demonstrate the push-pull of a drug-development business that targets "high unmet medical need" but requires hefty profit margins to stay in specific disease areas. Although new antibacterials are badly…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news